Amid Expected Enhertu Entry, Chinese Domestic ADC Developers Race To Market

'Fast-Follower' Strategy?

12 biotechs in China are preparing to compete for domestic market share for their home-grown HER2-targeted antibody-drug conjugates amid Enhertu’s in-roads in the country.

Chinese developers are flocking to ADC drugs after seeing chances of blockbuster success.
At least 12 HER2-targeted ADCs in clinical studies in China • Source: Alamy

Antibody-drug conjugate (ADC) developers in China are mulling over ways to put up a fight for future domestic market share, given that Daiichi Sankyo Co., Ltd./AstraZeneca PLC’s blockbuster ADC Enhertu (trastuzumab deruxtecan) is set to make inroads in the country over the coming months.

As evidenced by recent partnerships forged with US drug makers to out-license global rights to Claudin 18.2-targeted ADC candidates, some...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from China

  • Iran Deal In Place, But API Prices Stay Elevated And Pharma Supply Chains Face A Slow Recovery

    A framework to end the Iran war is in place but fractured supply chains can’t recover overnight. Data from India suggests solvent prices have generally cooled from April peaks, but API costs stay elevated or even climbed in June for some products.

  • Embracing China’s Brave New Pharmaceutical World!

     
    • By 

    Already one of the world’s largest pharmaceutical markets, China has tremendous growth potential, but significant policy and market changes are rocking the basis of competition. Multinational biopharma corporations cannot succeed in this new environment unless they fundamentally reinvent their business models to adapt to sweeping change.

  • Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

    Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from Focus On Asia